RESUMEN
BACKGROUND: Numerous studies suggest a progressive accumulation of post-translationally modified peptides within amyloid fibrils, including isoaspartate (isoD) modifications. Here, we generated and characterised novel monoclonal antibodies targeting isoD-modified transthyretin (TTR). The antibodies were used to investigate the presence of isoD-modified TTR in deposits from transthyretin amyloidosis patients and to mediate antibody-dependent phagocytosis of TTR fibrils. METHODS: Monoclonal antibodies were generated by immunisation of mice using an isoD-modified peptide and subsequent hybridoma generation. The antibodies were characterised in terms of affinity and specificity to isoD-modified TTR using surface plasmon resonance, transmission electron microscopy and immunohistochemical staining of human cardiac tissue. The potential to elicit antibody-dependent phagocytosis of TTR fibrils was assessed using THP-1 cells. RESULTS: We developed two mouse monoclonal antibodies, 2F2 and 4D4, with high nanomolar affinity for isoD-modified TTR and strong selectivity over the unmodified epitope. Both antibodies show presence of isoD-modified TTR in human cardiac tissue, but not in freshly purified recombinant TTR, suggesting isoD modification only present in aged fibrillar deposits. Likewise, the antibodies only facilitated phagocytosis of TTR fibrils and not TTR monomers by THP-1 cells. CONCLUSIONS: These antibodies label aged, non-native TTR deposits, leaving native TTR unattended and thereby potentially enabling new therapeutic approaches.
Asunto(s)
Neuropatías Amiloides Familiares , Anticuerpos Monoclonales , Inmunoterapia , Prealbúmina , Prealbúmina/inmunología , Prealbúmina/metabolismo , Prealbúmina/química , Humanos , Animales , Neuropatías Amiloides Familiares/inmunología , Neuropatías Amiloides Familiares/patología , Neuropatías Amiloides Familiares/metabolismo , Neuropatías Amiloides Familiares/terapia , Ratones , Anticuerpos Monoclonales/inmunología , Inmunoterapia/métodos , Amiloide/metabolismo , Amiloide/inmunología , Fagocitosis/inmunología , Células THP-1 , Femenino , Procesamiento Proteico-PostraduccionalRESUMEN
Amyloidosis is a group of diseases that includes Alzheimer's disease, prion diseases, transthyretin (ATTR) amyloidosis, and immunoglobulin light chain (AL) amyloidosis. The mechanism of organ dysfunction resulting from amyloidosis has been a topic of debate. This review focuses on the ultrastructure of tissue damage resulting from amyloid deposition and therapeutic insights based on the pathophysiology of amyloidosis. Studies of nerve biopsy or cardiac autopsy specimens from patients with ATTR and AL amyloidoses show atrophy of cells near amyloid fibril aggregates. In addition to the stress or toxicity attributable to amyloid fibrils themselves, the toxicity of non-fibrillar states of amyloidogenic proteins, particularly oligomers, may also participate in the mechanisms of tissue damage. The obscuration of the basement and cytoplasmic membranes of cells near amyloid fibrils attributable to an affinity of components constituting these membranes to those of amyloid fibrils may also play an important role in tissue damage. Possible major therapeutic strategies based on pathophysiology of amyloidosis consist of the following: (1) reducing or preventing the production of causative proteins; (2) preventing the causative proteins from participating in the process of amyloid fibril formation; and/or (3) eliminating already-deposited amyloid fibrils. As the development of novel disease-modifying therapies such as short interfering RNA, antisense oligonucleotide, and monoclonal antibodies is remarkable, early diagnosis and appropriate selection of treatment is becoming more and more important for patients with amyloidosis.
Asunto(s)
Enfermedad de Alzheimer/patología , Neuropatías Amiloides Familiares/patología , Amiloide/inmunología , Amiloidosis de Cadenas Ligeras de las Inmunoglobulinas/patología , Miocardio/patología , Nervios Periféricos/patología , Enfermedades por Prión/patología , Enfermedad de Alzheimer/tratamiento farmacológico , Enfermedad de Alzheimer/genética , Enfermedad de Alzheimer/inmunología , Amiloide/antagonistas & inhibidores , Amiloide/genética , Neuropatías Amiloides Familiares/tratamiento farmacológico , Neuropatías Amiloides Familiares/genética , Neuropatías Amiloides Familiares/inmunología , Benzoxazoles/uso terapéutico , Diflunisal/uso terapéutico , Humanos , Cadenas Ligeras de Inmunoglobulina/genética , Cadenas Ligeras de Inmunoglobulina/metabolismo , Amiloidosis de Cadenas Ligeras de las Inmunoglobulinas/tratamiento farmacológico , Amiloidosis de Cadenas Ligeras de las Inmunoglobulinas/genética , Amiloidosis de Cadenas Ligeras de las Inmunoglobulinas/inmunología , Factores Inmunológicos/uso terapéutico , Miocardio/inmunología , Fármacos Neuroprotectores/uso terapéutico , Oligonucleótidos/uso terapéutico , Nervios Periféricos/efectos de los fármacos , Nervios Periféricos/inmunología , Prealbúmina/antagonistas & inhibidores , Prealbúmina/genética , Prealbúmina/inmunología , Enfermedades por Prión/tratamiento farmacológico , Enfermedades por Prión/genética , Enfermedades por Prión/inmunología , ARN Interferente Pequeño/uso terapéuticoRESUMEN
Inotersen (TEGSEDI™) is a 2'-O-(2-methoxyethyl)-modified antisense oligonucleotide, intended for treating hereditary transthyretin (TTR) amyloidosis with polyneuropathy. The potential immunogenicity (IM) response to inotersen was evaluated in chronic nonclinical safety studies and the pivotal phase 2/3 clinical study. The evaluation was designed to assess the characteristics of antidrug antibodies (ADAs) and their effects on the pharmacokinetics, pharmacodynamics, clinical efficacy, and safety in animals and humans. No immunogenic response was observed after long-term treatment with inotersen in mice. In monkeys, the incidence rate of IM to inotersen appeared to be dose dependent, with 28.6%-50.0% of animals developing ADAs after 36 weeks of treatment. This was characterized as late onset (median onset of 185 days) with low titers (median titer of 8, or 400 if minimum required dilution of 50 is included). The overall incidence rate of patients who developed ADAs was 30% after 65 weeks of treatment with median onset of 203 days and median peak titer of 300. IM had minimal effect on plasma peak (Cmax) and total exposure (i.e. area under curve, AUC) of inotersen, but showed elevated plasma trough levels in both IM-positive animals and humans. However, ADAs had no effect on tissue exposure, TTR messenger RNA, or plasma TTR levels in the long-term monkey study. Similarly, IM showed no effect on plasma TTR levels in clinical studies. Thus, ADAs antibodies were binding antibodies, but not neutralizing antibodies. Finally, no association was observed between IM and toxicity findings (eg, platelet, complement activation, and histopathology findings) in the inotersen 9-month monkey study. In humans, no difference was observed in hematology, including platelets, kidney function tests, or incidence of adverse events between IM-positive and -negative patients. Overall, IM showed no effect on toxicity or safety of inotersen evaluated in both monkeys and humans. ClinicalTrials.gov Identifier: NCT01737398.
Asunto(s)
Enfermedad de Charcot-Marie-Tooth/tratamiento farmacológico , Oligonucleótidos Antisentido/administración & dosificación , Oligonucleótidos/administración & dosificación , Oligorribonucleótidos/administración & dosificación , Prealbúmina/genética , Animales , Anticuerpos Antiidiotipos/sangre , Anticuerpos Antiidiotipos/inmunología , Plaquetas/inmunología , Enfermedad de Charcot-Marie-Tooth/sangre , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/inmunología , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/patología , Femenino , Haplorrinos , Humanos , Inmunogenicidad Vacunal/genética , Inmunogenicidad Vacunal/inmunología , Pruebas de Función Renal , Masculino , Ratones , Oligonucleótidos/efectos adversos , Oligonucleótidos Antisentido/efectos adversos , Oligonucleótidos Antisentido/sangre , Oligonucleótidos Antisentido/farmacocinética , Oligorribonucleótidos/efectos adversos , Oligorribonucleótidos/sangre , Oligorribonucleótidos/farmacocinética , Prealbúmina/antagonistas & inhibidores , Prealbúmina/inmunologíaRESUMEN
The analysis of low abundant proteins in biological fluids by capillary electrophoresis (CE) is particularly problematic due to the typically poor concentration limits of detection of microscale separation techniques. Another important issue is sample matrix complexity that requires an appropriate cleanup. Here, we describe an on-line immunoaffinity solid-phase extraction capillary electrophoresis-mass spectrometry (IA-SPE-CE-MS) method for the immunoextraction, preconcentration, separation, detection, and characterization of serum transthyretin (TTR). TTR is a protein biomarker related to diverse types of amyloidosis, such as familial amyloidotic polyneuropathy type I (FAP-I), which is the most common hereditary systemic amyloidosis.
Asunto(s)
Cromatografía de Afinidad/métodos , Electroforesis Capilar/métodos , Espectrometría de Masas/métodos , Sistemas en Línea , Prealbúmina/análisis , Prealbúmina/inmunología , Suero/química , Extracción en Fase Sólida/métodos , Humanos , Estándares de ReferenciaRESUMEN
Early detection of lung cancer offers an important opportunity to decrease mortality while it is still treatable and curable. Thirteen secretory proteins that are Stat3 downstream gene products were identified as a panel of biomarkers for lung cancer detection in human sera. This panel of biomarkers potentially differentiates different types of lung cancer for classification. Among them, the transthyretin (TTR) concentration was highly increased in human serum of lung cancer patients. TTR concentration was also induced in the serum, bronchoalveolar lavage fluid, alveolar type II epithelial cells, and alveolar myeloid cells of the CCSP-rtTA/(tetO)7-Stat3C lung tumor mouse model. Recombinant TTR stimulated lung tumor cell proliferation and growth, which were mediated by activation of mitogenic and oncogenic molecules. TTR possesses cytokine functions to stimulate myeloid cell differentiation, which are known to play roles in tumor environment. Further analyses showed that TTR treatment enhanced the reactive oxygen species production in myeloid cells and enabled them to become functional myeloid-derived suppressive cells. TTR demonstrated a great influence on a wide spectrum of endothelial cell functions to control tumor and immune cell migration and infiltration. TTR-treated endothelial cells suppressed T cell proliferation. Taken together, these 13 Stat3 downstream inducible secretory protein biomarkers potentially can be used for lung cancer diagnosis, classification, and as clinical targets for lung cancer personalized treatment if their expression levels are increased in a given lung cancer patient in the blood.
Asunto(s)
Células Endoteliales/inmunología , Regulación Neoplásica de la Expresión Génica , Neoplasias Pulmonares/inmunología , Prealbúmina/inmunología , Células Epiteliales Alveolares/inmunología , Animales , Biomarcadores de Tumor/sangre , Líquido del Lavado Bronquioalveolar/química , Movimiento Celular , Proliferación Celular , Modelos Animales de Enfermedad , Humanos , Neoplasias Pulmonares/clasificación , Melanoma Experimental , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos , Células Mieloides/inmunología , Neoplasias Experimentales/inmunología , Prealbúmina/farmacología , Proteínas Recombinantes/farmacología , Factor de Transcripción STAT3/genéticaRESUMEN
Background: Patient immune response is one of the main factors influencing hepatitis virus (HBV) eradication or chronicity. Our study aimed to investigate the relationship between the nutritional status and immune function, and to provide the appropriate clinical diagnosis data for treatment of patients with chronic hepatitis B virus (CHB) and cirrhosis. Methods: T lymphocyte subsets were tested using flow cytometry in 100 patients (48 with CHB, 52 with cirrhosis) and 26 healthy individuals. Nutritional parameters were analyzed including body mass index (BMI), blood white blood cell count, albumin, prealbumin, and biochemistry parameters in patient and control groups. Results: Moderate and severe malnutrition (53.84%) were observed in HBV-cirrhosis patients. Serum albumin and prealbumin levels were the lowest in the cirrhosis group. There were significantly lower levels of lymphocyte subsets (CD3+, CD3+CD4+, and CD3+CD8+) in patient groups compared with the control group. There was significantly lower cholesterol, white blood cells, lymphocytes, and platelet levels in the patient group compared with the control group. Interrelation between nutritional and immune parameters showed that serum prealbumin levels were negatively correlated with CD3+, CD3+CD4+, and CD3+CD8+ count in the CHB group, and the immune parameters (CD3+, CD3+CD4+, and CD3+CD8+ count) correlated significantly with BMI in the patients with cirrhosis (r > 0.45). Conclusions: Our data demonstrate that there is a correlation between nutrition deficiency and immune dysfunction in patients with CHB and cirrhosis. It is necessary to assess the nutritional status and immune balance in these patients.
Asunto(s)
Índice de Masa Corporal , Estado Nutricional , Prealbúmina/inmunología , Subgrupos de Linfocitos T/inmunología , Adulto , Femenino , Virus de la Hepatitis B/inmunología , Virus de la Hepatitis B/fisiología , Hepatitis B Crónica/complicaciones , Hepatitis B Crónica/inmunología , Hepatitis B Crónica/virología , Humanos , Cirrosis Hepática/complicaciones , Cirrosis Hepática/inmunología , Cirrosis Hepática/virología , Recuento de Linfocitos , Masculino , Persona de Mediana Edad , Evaluación Nutricional , Prealbúmina/metabolismo , Subgrupos de Linfocitos T/metabolismoRESUMEN
Commercial antibodies against varying proteins are often not optimal for identification of proteins in their amyloid fibril forms. Reasons can be the different conformation but also a variety of modifications like N- or C-terminal truncation. Therefore, development of own monoclonal antibodies against amyloid fibril proteins may be advantageous. This chapter gives suggestions of how to be successful in such approaches.
Asunto(s)
Anticuerpos Monoclonales de Origen Murino/metabolismo , Prealbúmina/química , Prealbúmina/inmunología , Amiloidosis/diagnóstico , Amiloidosis/genética , Amiloidosis/metabolismo , Animales , Epítopos/metabolismo , Humanos , Hibridomas/citología , Hibridomas/metabolismo , Ratones , Prealbúmina/genética , ConejosRESUMEN
This paper describes an on-line immunoaffinity solid-phase extraction capillary electrophoresis mass spectrometry (IA-SPE-CE-MS) method using an immunoaffinity sorbent with Fab' antibody fragments (Fab'-IA) for the analysis of serum transthyretin (TTR), a homotetrameric protein (Mr~56,000) involved in different types of amyloidosis. The IA sorbent was prepared by covalent attachment of Fab' fragments obtained from a polyclonal IgG antibody against TTR to succinimidyl silica particles. The Fab'-IA-SPE-CE-MS methodology was first established analyzing TTR standard solutions. Under optimized conditions, repeatability and reproducibility were acceptable, the method was linear between 1 and 25µgmL-1, limits of detection (LODs) were around 0.5µgmL-1 (50-fold lower than by CE-MS, ~25µgmL-1) and different TTR conformations were observed (folded and unfolded). The applicability of the developed method to screen for familial amyloidotic polyneuropathy type I (FAP-I), which is the most common hereditary systemic amyloidosis, was evaluated analyzing serum samples from healthy controls and FAP-I patients. For the analysis of sera, the most abundant proteins were precipitated with 5% (v/v) of phenol before Fab'-IA-SPE-CE-MS. The current method enhanced our previous results for the analysis of TTR using intact antibodies immobilized on magnetic beads. It allowed a slight improvement on LODs (2-fold), the detection of proteoforms found at lower concentrations and the preparation of microcartridges with extended durability.
Asunto(s)
Análisis Químico de la Sangre/métodos , Electroforesis Capilar , Fragmentos Fab de Inmunoglobulinas/inmunología , Espectrometría de Masas , Prealbúmina/análisis , Extracción en Fase Sólida , Humanos , Prealbúmina/inmunologíaAsunto(s)
Neuropatías Amiloides Familiares/tratamiento farmacológico , Neuropatías Amiloides/tratamiento farmacológico , Anticuerpos/uso terapéutico , Prealbúmina/antagonistas & inhibidores , Neuropatías Amiloides/inmunología , Neuropatías Amiloides Familiares/inmunología , Femenino , Humanos , Masculino , Prealbúmina/inmunologíaRESUMEN
Familial amyloidotic polyneuropathy (FAP) is a systemic amyloidosis mainly caused by amyloidogenic transthyretin (ATTR). This incurable disease causes death â¼10 years after onset. Although it has been widely accepted that conformational change of the monomeric form of transthyretin (TTR) is very important for amyloid formation and deposition in the organs, no effective therapy targeting this step is available. In this study, we generated a mouse monoclonal antibody, T24, that recognized the cryptic epitope of conformationally changed TTR. T24 inhibited TTR accumulation in FAP model rats, which expressed human ATTR V30M in various tissues and exhibited non-fibrillar deposits of ATTR in the gastrointestinal tracts. Additionally, humanized T24 (RT24) inhibited TTR fibrillation and promoted macrophage phagocytosis of aggregated TTR. This antibody did not recognize normal serum TTR functioning properly in the blood. These results demonstrate that RT24 would be an effective novel therapeutic antibody for FAP.
Asunto(s)
Neuropatías Amiloides Familiares/tratamiento farmacológico , Neuropatías Amiloides Familiares/inmunología , Anticuerpos Monoclonales de Origen Murino/inmunología , Macrófagos/inmunología , Fagocitosis/efectos de los fármacos , Prealbúmina/inmunología , Neuropatías Amiloides Familiares/patología , Animales , Anticuerpos Monoclonales de Origen Murino/uso terapéutico , Femenino , Humanos , Macrófagos/patología , Masculino , Ratones , RatasRESUMEN
Wild-type and mutant transthyretin (TTR) can misfold and deposit in the heart, peripheral nerves, and other sites causing amyloid disease. Pharmacological chaperones, Tafamidis(®) and diflunisal, inhibit TTR misfolding by stabilizing native tetrameric TTR; however, their minimal effective concentration is in the micromolar range. By immune-targeting sparsely populated TTR misfolding intermediates (i.e. monomers), we achieved fibril inhibition at substoichiometric concentrations. We developed an antibody (misTTR) that targets TTR residues 89-97, an epitope buried in the tetramer but exposed in the monomer. Nanomolar misTTR inhibits fibrillogenesis of misfolded TTR under micromolar concentrations. Pan-specific TTR antibodies do not possess such fibril inhibiting properties. We show that selective targeting of misfolding intermediates is an alternative to native state stabilization and requires substoichiometric concentrations. MisTTR or its derivative may have both diagnostic and therapeutic potential.
Asunto(s)
Anticuerpos/inmunología , Prealbúmina/inmunología , Prealbúmina/metabolismo , Pliegue de Proteína , Amiloidosis/diagnóstico , Amiloidosis/terapia , Animales , Inmunoterapia/métodos , Unión Proteica , ConejosRESUMEN
INTRODUCTION: Transthyretin amyloidosis (ATTR amyloidosis) is caused by the misfolding and deposition of the transthyretin (TTR) protein and results in progressive multi-organ dysfunction. TTR epitopes exposed by dissociation and misfolding are targets for immunotherapeutic antibodies. We developed and characterized antibodies that selectively bound to misfolded, non-native conformations of TTR. METHODS: Antibody clones were generated by immunizing mice with an antigenic peptide comprising a cryptotope within the TTR sequence and screened for specific binding to non-native TTR conformations, suppression of in vitro TTR fibrillogenesis, promotion of antibody-dependent phagocytic uptake of mis-folded TTR and specific immunolabeling of ATTR amyloidosis patient-derived tissue. RESULTS: Four identified monoclonal antibodies were characterized. These antibodies selectively bound the target epitope on monomeric and non-native misfolded forms of TTR and strongly suppressed TTR fibril formation in vitro. These antibodies bound fluorescently tagged aggregated TTR, targeting it for phagocytic uptake by macrophage THP-1 cells, and amyloid-positive TTR deposits in heart tissue from patients with ATTR amyloidosis, but did not bind to other types of amyloid deposits or normal tissue. CONCLUSIONS: Conformation-specific anti-TTR antibodies selectively bind amyloidogenic but not native TTR. These novel antibodies may be therapeutically useful in preventing deposition and promoting clearance of TTR amyloid and in diagnosing TTR amyloidosis.
Asunto(s)
Anticuerpos Monoclonales/química , Complejo Antígeno-Anticuerpo/química , Epítopos/química , Fagocitosis , Prealbúmina/química , Secuencia de Aminoácidos , Neuropatías Amiloides Familiares/complicaciones , Neuropatías Amiloides Familiares/metabolismo , Neuropatías Amiloides Familiares/patología , Animales , Anticuerpos Monoclonales/biosíntesis , Anticuerpos Monoclonales/aislamiento & purificación , Cardiomiopatías/complicaciones , Cardiomiopatías/metabolismo , Cardiomiopatías/patología , Línea Celular , Células Clonales , Humanos , Ratones , Miocardio/química , Miocardio/metabolismo , Miocardio/patología , Fagocitos/citología , Fagocitos/inmunología , Prealbúmina/inmunología , Agregado de Proteínas/inmunología , Conformación Proteica , Pliegue de Proteína , Proteínas Recombinantes/química , Proteínas Recombinantes/inmunologíaRESUMEN
Characterized by hypertension and proteinuria after the 20th week of gestation, pre-eclampsia (PE) is a major cause of maternal, fetal, and neonatal morbidity and mortality. Despite being recognized for centuries, PE still lacks a reliable, early means of diagnosis or prediction, and a safe and effective therapy. We have recently reported that the event of toxic protein misfolding and aggregation is a critical etiological manifestation in PE. Using comparative proteomic analysis of gestational age-matched sera from PE and normal pregnancy, we identified several proteins that appeared to be dysregulated in PE. Our efforts so far have focused on transthyretin (TTR), a transporter of thyroxine and retinol, and amyloid precursor protein whose aggregates were detected in the PE placenta. Based on these results and detection of TTR aggregates in sera from PE patients, we proposed that PE could be a disease of protein misfolding and aggregation. Protein misfolding and aggregation have long been linked with many neurodegenerative diseases such as Alzheimer's disease. However, linkage of protein misfolding and aggregation with the PE pathogenesis is a new and novel concept. This review aims to understand the roles of aggregated proteins in PE using the cues from the Alzheimer's etiology.
Asunto(s)
Enfermedad de Alzheimer/inmunología , Precursor de Proteína beta-Amiloide/inmunología , Preeclampsia/inmunología , Prealbúmina/inmunología , Agregación Patológica de Proteínas/inmunología , Enfermedad de Alzheimer/patología , Animales , Femenino , Preeclampsia/patología , Embarazo , Agregación Patológica de Proteínas/patologíaRESUMEN
Rheumatoid arthritis (RA) is a chronic, autoimmune, systemic and inflammatory rheumatic disease that leads to inflammation of the joints and surrounding tissues. Identification of novel protein(s) associated with severity of RA is a prerequisite for better understanding of pathogenesis of this disease that may also have potential to serve as novel biomarkers in the diagnosis of RA. Present study was undertaken to compare the amount of autoantigens and autoantibodies in the plasma of RA patients in comparison to healthy controls. Plasma samples were collected from the patients suffering from RA, Osteoarthritis (OA), Systemic lupus erythematosus (SLE) and healthy volunteers. The screening of plasma proteins were carried out using 2-dimensional gel electrophoresis followed by identification of differentially expressed protein by MALDI-TOF MS/MS. Among several differentially expressed proteins, transthyretin (TTR) has been identified as one of the protein that showed significantly up regulated expression in the plasma of RA patients. The results were further validated by Western blot analysis and ELISA. In comparison to OA synovium, an exclusive significantly high expression of TTR in RA has been validated through IHC, Western blotting and IEM studies. Most importantly, the increase in expression of TTR with the progression of severity of RA condition has been observed. The autoantibodies against TTR present in the RA plasma were identified using immunoprecipitation-Western methods. The significant production of autoantibodies was validated by ELISA and Western blot analysis using recombinant pure protein of TTR. Hence, these novel observations on increase in TTR expression with the increase in severity of RA conditions and significant production of autoantibodies against TTR clearly suggest that a systematic studies on the role TTR in the pathogenesis of RA is immediately required and TTR may be used as a serum diagnostic marker together with other biochemical parameters and clinical symptoms for RA screening and diagnosis.
Asunto(s)
Artritis Reumatoide/diagnóstico , Autoanticuerpos/sangre , Prealbúmina/inmunología , Adolescente , Adulto , Anciano , Artritis Reumatoide/sangre , Artritis Reumatoide/inmunología , Biomarcadores , Femenino , Humanos , Lupus Eritematoso Sistémico/sangre , Lupus Eritematoso Sistémico/inmunología , Masculino , Persona de Mediana Edad , Osteoartritis/sangre , Osteoartritis/inmunología , Adulto JovenRESUMEN
Peptide bond-hydrolyzing catalytic antibodies (catabodies) could degrade toxic proteins, but acquired immunity principles have not provided evidence for beneficial catabodies. Transthyretin (TTR) forms misfolded ß-sheet aggregates responsible for age-associated amyloidosis. We describe nucleophilic catabodies from healthy humans without amyloidosis that degraded misfolded TTR (misTTR) without reactivity to the physiological tetrameric TTR (phyTTR). IgM class B cell receptors specifically recognized the electrophilic analog of misTTR but not phyTTR. IgM but not IgG class antibodies hydrolyzed the particulate and soluble misTTR species. No misTTR-IgM binding was detected. The IgMs accounted for essentially all of the misTTR hydrolytic activity of unfractionated human serum. The IgMs did not degrade non-amyloidogenic, non-superantigenic proteins. Individual monoclonal IgMs (mIgMs) expressed variable misTTR hydrolytic rates and differing oligoreactivity directed to amyloid ß peptide and microbial superantigen proteins. A subset of the mIgMs was monoreactive for misTTR. Excess misTTR was dissolved by a hydrolytic mIgM. The studies reveal a novel antibody property, the innate ability of IgMs to selectively degrade and dissolve toxic misTTR species as a first line immune function.
Asunto(s)
Amiloide/metabolismo , Anticuerpos Catalíticos/metabolismo , Inmunoglobulina M/metabolismo , Prealbúmina/metabolismo , Proteolisis , Adulto , Amiloide/inmunología , Anticuerpos Catalíticos/inmunología , Especificidad de Anticuerpos/inmunología , Femenino , Humanos , Inmunoglobulina M/inmunología , Masculino , Prealbúmina/inmunologíaRESUMEN
Amyloidosis involves the extracellular deposition of proteinaceous amyloid fibrils and accessory molecules in organ(s) and/or tissue(s), and is associated with a host of human diseases, including Alzheimer disease, diabetes, and heart disease. Unfortunately, the amyloidoses are currently incurable, and there is an urgent need for less invasive diagnostics. To address this, we have generated 22 monoclonal antibodies (mAbs) against aggregates formed by a blood transport protein, transthyretin (TTR), which primarily forms amyloid fibrils in a patient's heart and/or peripheral nerves. Four of the mAbs, 2T5C9, 2G9C, T1F11, and TB2H7, demonstrated diagnostic potential in enzyme-linked immunosorbent assays (ELISA) by their low to sub-nanomolar cross-reactivity with recombinant wild-type (WT) and mutant TTR aggregates and lack of binding to native TTR or amyloid fibrils formed by other peptides or proteins. Notably, in the presence of normal human sera, three of the four mAbs, 2T5C9, 2G9C, and T1F11, retained low nM binding to TTR amyloid fibrils derived from two patients with familial amyloidotic polyneuropathy (FAP). The two most promising mAbs, 2T5C9 and 2G9C, were also shown by immunohistochemistry to have low nM binding to TTR amyloid deposits in cardiac tissue sections from two FAP patients. Taken together, these findings strongly support further investigations on the diagnostic utility of TTR aggregate specific mAbs for patients with TTR amyloidoses.
Asunto(s)
Amiloide/inmunología , Anticuerpos Monoclonales/inmunología , Especificidad de Anticuerpos/inmunología , Epítopos/inmunología , Prealbúmina/inmunología , Agregado de Proteínas/inmunología , Amiloide/ultraestructura , Animales , Reacciones Cruzadas/inmunología , Humanos , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Proteínas Mutantes/inmunología , Prealbúmina/ultraestructura , Suero/metabolismo , SolubilidadRESUMEN
BACKGROUND: This study investigated whether a relationship exists between the presence of de novo antibodies and the clinical manifestations of familial amyloidotic polyneuropathy (FAP). METHODS: Serum samples were collected from 25 Japanese and 6 Swedish FAP amyloidogenic transthyretin (ATTR) Valine30Methionine (V30M) patients, 4 asymptomatic Japanese ATTR V30M gene carriers, and 24 Japanese healthy volunteers. Study methods included enzyme-linked immunosorbent assay (ELISA) and mass spectrometry. RESULTS: Three Japanese and 5 Swedish patients had significantly higher levels of antibodies against ATTR than did healthy volunteers and asymptomatic gene carriers (P<0.05). All 8 patients with higher antibody levels were late-onset cases. The ratio of wild-type TTR to ATTR V30M in serum from the high-antibody group was higher than that of the low-antibody group. ELISA results revealed two epitopes at positions 24-35 and 105-115 of ATTR V30M. We found a significant positive correlation between levels of the antibody at positions 24-35 and the age at FAP onset (r=0.751, P<0.05). An age-dependent increase in the occurrence of antibodies was observed in these patients with an epitope at positions 24-35. CONCLUSIONS: These findings may help explain the differences in early- and late-onset FAP and/or the progression of FAP.
Asunto(s)
Neuropatías Amiloides Familiares/inmunología , Neuropatías Amiloides Familiares/patología , Amiloide/sangre , Amiloide/inmunología , Anticuerpos/inmunología , Prealbúmina/inmunología , Adulto , Edad de Inicio , Anciano , Anciano de 80 o más Años , Amiloide/genética , Neuropatías Amiloides Familiares/sangre , Anticuerpos/sangre , Reacciones Antígeno-Anticuerpo , Progresión de la Enfermedad , Ensayo de Inmunoadsorción Enzimática , Femenino , Humanos , Japón , Masculino , Espectrometría de Masas , Fenotipo , Prealbúmina/genética , SueciaRESUMEN
Transthyretin (TTR)-related familial amyloidotic polyneuropathy (FAP) is characterized by systemic accumulation of amyloid fibrils caused by a point mutation in the TTR gene. Despite the urgent need for alternative therapeutic strategies, the pathogenesis of FAP still remains elusive. In our study reported here, we focused on albumin, the most abundant protein in plasma, and described the role of albumin in the TTR amyloid-formation process. Patients with FAP evidenced significantly decreased serum albumin levels as the disease progressed. Biacore analysis showed that albumin had a binding affinity for TTR and exhibited higher affinity for TTR amyloid than native TTR. Albumin functioning as an antioxidant effectively suppressed TTR amyloid formation. In patients with FAP, albumin was significantly oxidized as the disease progressed. Moreover, loss of functional albumin accelerated TTR deposition in analbuminemic rats possessing a human variant TTR gene. Taken together, these results indicate that albumin may have an inhibitory role in the TTR amyloid-formation process.
Asunto(s)
Neuropatías Amiloides Familiares/metabolismo , Amiloide/metabolismo , Prealbúmina/metabolismo , Neuropatías Amiloides Familiares/genética , Animales , Antioxidantes/metabolismo , Ensayo de Inmunoadsorción Enzimática , Humanos , Estrés Oxidativo , Prealbúmina/inmunología , Estructura Cuaternaria de Proteína , Ratas , Ratas Sprague-Dawley , Ratas TransgénicasRESUMEN
A total of 227 sera were analysed using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) to find novel serum biomarkers for lung cancer. The results showed that the 11.53, 11.70, 13.78, 13.90 and 14.07 k m/z peaks identified as native serum amyloid A (SAA), SAA with N-terminal Arg cleaved, native transthyretin (TTR) and its two variants significantly differentiated lung cancer sera from normal control sera (p <0.01). A 'biomarker pattern' combining SAA and TTR was tested to distinguish lung cancer patients from normal control individuals, and the diagnostic positive rate of lung cancer was improved to 91.6%.